EyePoint (EYPT) Enterprise Value (2010 - 2026)
EyePoint (EYPT) posted Enterprise Value of -$222.5 million for Q1 2026, up 27.29% sequentially from -$306.1 million in Q4 2025, and up 30.06% YoY from -$171.1 million in Q1 2025.
Analysis
EyePoint (EYPT) Enterprise Value (2010 - 2026) Analysis & Trends
EyePoint has reported Enterprise Value for 17 years, with the latest figure at -$222.5 million in Q1 2026.
- Quarterly Enterprise Value rose 30.06% year-over-year to -$222.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$222.5 million (up 30.06% YoY) and the FY2025 annual result came in at -$306.1 million, up 17.48% from the prior year.
- Enterprise Value rose to -$222.5 million in Q1 2026 per EYPT's latest filing, from -$306.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$122.5 million in Q1 2023 and troughed at -$370.9 million in Q4 2024.
- A 5-year average of -$229.8 million and a median of -$222.5 million in 2026 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value soared 35.81% in 2023, then sank 144.44% in 2024.
- Over 5 years, Enterprise Value stood at -$144.6 million in 2022, then tumbled by 129.0% to -$331.0 million in 2023, then decreased by 12.04% to -$370.9 million in 2024, then advanced by 17.48% to -$306.1 million in 2025, then grew by 27.29% to -$222.5 million in 2026.
- According to Business Quant data, Enterprise Value over the past three periods registered -$222.5 million, -$306.1 million, and -$204.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.03 Bn |
| Mar 31, 2026 | 853.16 Mn |
| Dec 31, 2025 | 1.21 Bn |
| Sep 30, 2025 | 786.65 Mn |
| Jun 30, 2025 | 392.52 Mn |
| Mar 31, 2025 | 54.76 Mn |
| Dec 31, 2024 | 48.51 Mn |
| Sep 30, 2024 | 173.87 Mn |
| Jun 30, 2024 | 173.55 Mn |
| Mar 31, 2024 | 731.79 Mn |
| Dec 31, 2023 | 568.02 Mn |
| Sep 30, 2023 | 146.09 Mn |
| Jun 30, 2023 | 155.93 Mn |
| Mar 31, 2023 | -21.64 Mn |
| Dec 31, 2022 | -25.27 Mn |
| Sep 30, 2022 | 112.25 Mn |
| Jun 30, 2022 | 96.83 Mn |
| Mar 31, 2022 | 222.89 Mn |
| Dec 31, 2021 | 203.41 Mn |
| Sep 30, 2021 | 180.09 Mn |